We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
Consensus vs. actual, and revenue trend
Consensus PT $5.88 · 2 analysts
Biofrontera targets cash flow breakeven in 2026 while aiming for 80%-85% gross margin - MSN
Biofrontera targets cash flow breakeven in 2026 while aiming for 80%-85% gross margin MSN
Biofrontera Inc. Warrants (BFRIW) Holds Steady at $0.03 – Tight Range Signals Stalemate for Penny-Stock Warrants - Fear Greed Index - dars.gov.et
Biofrontera Inc. Warrants (BFRIW) Holds Steady at $0.03 – Tight Range Signals Stalemate for Penny-Stock Warrants - Fear Greed Index dars.gov.et
Biofrontera Inc. (BFRI) Slides 3.5% as Stock Tests Key Support Near $1.04 - Liquidity Sweep - dars.gov.et
Biofrontera Inc. (BFRI) Slides 3.5% as Stock Tests Key Support Near $1.04 - Liquidity Sweep dars.gov.et
Biofrontera Inc. (BFRI) Slides 3.5% as Stock Tests Key Support Near $1.04 - Hagopian Line - dars.gov.et
Biofrontera Inc. (BFRI) Slides 3.5% as Stock Tests Key Support Near $1.04 - Hagopian Line dars.gov.et
Biofrontera’s Acne PDT Trial Completion: What Investors Should Watch Next - TipRanks
Biofrontera’s Acne PDT Trial Completion: What Investors Should Watch Next TipRanks
Enterprise value to EBITDA forward of Biofrontera Inc. – NASDAQ:BFRI - TradingView
Enterprise value to EBITDA forward of Biofrontera Inc. – NASDAQ:BFRI TradingView
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | After market close (AMC) | $-0.04 | — | — | $9.5M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.47 | — | — | $8.59M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-3.39 | — | — | $24.76M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-2.45 | — | — | $15.75M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | Benchmark | — | Downgrade | Buy → Speculative Buy | — | Benchmark: Buy → Speculative Buy |
| 2025. 05. 19. | Benchmark | — | Maintain | Buy → Buy | — | Benchmark: Buy |
| 2024. 11. 16. | Benchmark | — | Maintain | Buy → Buy | — | Benchmark: Buy |
| 2024. 08. 16. | Benchmark | — | Maintain | Buy → Buy | — | Benchmark: Buy |
| 2023. 08. 31. | Benchmark | — | Maintain | Buy → Buy | — | Benchmark: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.